Heavy alcohol consumption is a major cause of morbidity and mortality. Globally, alcohol per-
capita consumption rose from 5.5 litres in 2005 to 6.4 litres in 2016 and is projected to …

Executive summary Liver diseases have become a major health threat across Europe, and
the face of European hepatology is changing due to the cure of viral hepatitis C and the …

Non-invasive tests are increasingly being used to improve the diagnosis and
prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest …

To test the hypothesis that the gut microbiota of individuals with nonalcoholic fatty liver
disease (NAFLD) produce enough ethanol to be a driving force in the development and …

This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty
liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and …

Liver diseases are fast emerging as global health priorities. Fatty liver is described in the
setting of non-alcoholic fatty liver disease (NAFLD) as well as alcoholic liver disease (ALD) …

Abstract The coronavirus disease 2019 (COVID‐19) pandemic has had a tremendous global
impact since it began in November of 2019. However, there are concerns that the COVID‐19 …

Abstract “Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term
suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation …

Silymarin, an extract from milk thistle seeds, has been used for centuries to treat hepatic
conditions. Preclinical data indicate that silymarin can reduce oxidative stress and …

Liver biopsy is required when clinically important information about the diagnosis, prognosis
or management of a patient cannot be obtained by safer means, or for research purposes …